

**Engagement Report for Clinical Commissioning Policies**

<b>Unique Reference Number</b>	F01X07
<b>Policy Title</b>	Second allogeneic haematopoietic stem cell transplant for relapsed disease
<b>Accountable Commissioner</b>	Claire Foreman
<b>Clinical Reference Group</b>	Blood & Marrow Transplantation
Which stakeholders were contacted to be involved in policy development?	All CRG members and registered stakeholders British Society of Blood and Marrow Transplantation (BSBMT) Paediatric Cancer CRG members
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG.
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment.
Explain reason if there is any difference from previous question	Not applicable.
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	None.

**FOR PUBLIC CONSULTATION ONLY**

<p>How have the stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy was circulated to the full membership of the CRG and registered stakeholders for one week for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be.</p> <p>Five responses were received in total; three from CRG members and two from CRG stakeholders. All responses were supportive of both the policy proposition and the proposed commissioning position.</p> <p>(1) Two stakeholders noted that the SPH clinical evidence review had omitted a specific study, published in 2008.</p> <p>(2) Two stakeholders raised a concern about the policy excluding children and the impact this will have on the commissioning of 2nd HSCTs for this patient group.</p> <p>(3) All stakeholders suggested further interested parties with whom NHS England should engage as part of the policy development process.</p> <p>All stakeholders supported a 30 day period of public consultation.</p>
<p>What has happened or changed as a result of their input?</p>	<p>Stakeholders were invited to comment. The Policy Working Group (PWG) responses to stakeholder comments can be summarised as follows:</p> <ul style="list-style-type: none"> <li>- In response to (1), the PWG notes that the search strategy included only papers published in 2012 onwards.</li> <li>- In response to (2), the PWG agrees that, whilst the evidence review focused on adults, second transplants for relapsed disease are a relevant treatment option for children. Data from the BSBMT (in full) demonstrates that outcomes following HSCT are generally superior in children to those in adults across all indications.</li> <li>- In response to (3), the PWG will take this as an action and ensure these stakeholders are contacted during public consultation.</li> </ul> <p>On the basis of (2), NHS England has agreed to update this policy proposition to recommend access to patients of all ages meeting the commissioning criteria.</p>
<p>How are stakeholders been informed of progress with policy development as a result of their input?</p>	<p>This engagement report, along with the updated policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Public consultation for a period of 30 days as supported by stakeholders.</p>